Here, we sought to assemble a class of CRISPRa-based immunostimulatory circuits, which could enable accurate tumor targeting upon co-detection of the highly tumor-characteristic p53 deficiency together with a frequent event(s) of TF activation (in a dual-input, AND–NOT logic). The gene discussed is TP53; the disease is neoplasm.